Treatment Planning for HER2+ Breast Cancer: The Role of Ovarian Function Suppression

Video content above is prompted by the following:

Fertility Preservation and Ovarian Suppression

Key Themes:

• Ovarian suppression recommendations
  • Based on SOFT/TEXT trial data, showing benefit for high-risk premenopausal patients
  • Particularly beneficial for patients under 35 years of age
  • Recommended for patients receiving chemotherapy or considered high risk
  • HER2-positive patients may benefit from ovarian suppression
• HERA trial analysis
  • Recent analysis presented at ESMO 2024 examined premenopausal women with triple-positive breast cancer
  • Found survival outcomes of ovarian function suppression plus aromatase inhibitor superior to ovarian function suppression plus tamoxifen
  • Ovarian function suppression combined with endocrine therapy was superior to tamoxifen alone

Notable Insights:

• Dr Vidal shared: “For my premenopausal hormone receptor–positive patients for whom I think there’s high risk, those patients, I definitely add ovarian suppression.”
• Dr McCann emphasized: “I always tell my patients that my favorite medication for them is the one they’re willing to take.”